



September 1, 2019

**RE: Anthem expands specialty pharmacy prior authorization list**

Dear Provider:

Anthem Blue Cross and Blue Shield and our subsidiary company, HMO Nevada (collectively Anthem) will be expanding the Specialty Pharmacy prior authorization list.

Effective for dates of service on and after December 1, 2019, the following non-oncology specialty pharmacy codes from current clinical criteria will be included in our prior authorization review process.

Please note, inclusion of NDC code on your claim will shorten the claim processing time of drugs billed with a Not Otherwise Classified (NOC) code.

Anthem’s prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Anthem’s medical specialty drug review team. Oncology drugs will be managed by AIM Specialty Health® (AIM), a separate company.

Clinical Criteria	HCPCS or CPT Code(s)	NDC Code(s)	Drug
ING-CC-0031	J3490	71879-0136-01	Yutiq™
ING-CC-0003	J3490 J3590 C9399	68982-0810-01 68982-0810-02 68982-0810-03 68982-0810-04 68982-0810-05 68982-0810-06	Cutaquig®
ING-CC-0003	J1599	69800-0250-01	Asceniv™

**Clinical criteria updates for specialty pharmacy**

Clinical criteria ING-CC-0061 addresses the use of gonadotropin releasing hormone analogs for the treatment of non-oncologic indications.

Effective for dates of service on and after December 1, 2019, the use of Zoladex for the treatment of endometriosis will be limited to 6 months.

To access the clinical criteria information, go to: [www11.anthem.com/pharmacyinformation/clinicalcriteria.html](http://www11.anthem.com/pharmacyinformation/clinicalcriteria.html)

We value and appreciate you as our partner in providing quality care, and appreciate your continued participation in our network.

Sincerely,

Allen Marino, M.D.  
Medical Director  
Anthem Blue Cross and Blue Shield